Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies

BACKGROUND: Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Singleton, Kyle W, Porter, Alyx B, Hu, Leland S, Johnston, Sandra K, Bond, Kamila M, Rickertsen, Cassandra R, De Leon, Gustavo, Whitmire, Scott A, Clark-Swanson, Kamala R, Mrugala, Maciej M, Swanson, Kristin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447137/
https://www.ncbi.nlm.nih.gov/pubmed/32864609
http://dx.doi.org/10.1093/noajnl/vdaa085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447137/
https://www.ncbi.nlm.nih.gov/pubmed/32864609
http://dx.doi.org/10.1093/noajnl/vdaa085

Ejemplares similares